In an APP/PS1 mouse model, bone marrow mesenchymal stem cells—VEGF treatment improved endothelial dysfunction, neovascularization and reduced senile plaques in the hippocampus with impact on cognitive dysfunction of AD transgenic animals (Garcia et al., 2014). The gene discussed is APP; the disease is Alzheimer disease.